Target-gated design
How can systemic closure and tumor-local gate engagement create a selective cargo-receptor occupancy window?
Target-Gated Cargo QSP
5 starting configurations Open model
Modeling
Explore 83 PK/PD and QSP models. Adjust inputs and compare simulation results.
Featured models
Explore models by research question
Exposure and response
How does nivolumab exposure connect to competing tumor shrinkage and progression?
Nivolumab exposure and tumor-size dynamics
Reference paper ↗3 starting configurations Open model
Biomarker dynamics
How do rituximab exposure, B-cell depletion, and repopulation interact over time?
Rituximab exposure and CD19-positive B-cell dynamics
Reference paper ↗2 starting configurations Open model
Model search
Find a model
83 models · Showing 1–24
AAV8-encoded trastuzumab
PBPKQSP Gene-delivered antibody General pharmacology
Whole-body AAV8 gene-delivery and transgene-antibody PBPK
Reference paper ↗Mechanistic mouse PBPK/QSP coupling whole-body AAV8 disposition, receptor-mediated cell entry, nuclear vector, nonlinear dose-dependent transgene expression, FcRn-aware trastuzumab PBPK, and delayed immune loss.
- Therapeutic
- AAV8-encoded trastuzumab
- Target
- HER2 (antibody identity only, no target-binding module)
3 starting configurations Model details
AAV9/AAV5-encoded anti-TargetX monoclonal antibody
PBPKQSPTMDD Gene-delivered antibody Neurology & neurodegeneration
Whole-body AAV–anti-TargetX rat brain QSP
Reference paper ↗Mechanistic rat QSP coupling whole-body AAV biodistribution, intracellular transduction, transgene-derived anti-TargetX mAb, FcRn-aware protein PBPK, TargetX binding, and detailed brain/CSF transport across 725 explicit scalar states.
- Therapeutic
- AAV9/AAV5-encoded anti-TargetX monoclonal antibody
- Target
- TargetX (anonymized paper target)
12 starting configurations Model details
Adalimumab
Monoclonal antibody Autoimmune diseaseImmunology & inflammation
Adalimumab exposure across adult IBD reference models
Reference paper ↗SC absorption and apparent one-compartment disposition, with six rounded reference calculations and separate source-specific conditional covariate variants.
- Therapeutic
- Adalimumab
- Target
- TNF / TNFA
12 starting configurations Model details
Ado-trastuzumab emtansine
Antibody–drug conjugate (ADC) Oncology
T-DM1 serum exposure with baseline covariates
Reference paper ↗Conditional fixed-effect T-DM1 two-compartment PK with reversible distribution, linear clearance and baseline covariate effects. Predicts serum exposure without payload release, HER2 binding, tumor response or population variability.
- Therapeutic
- Ado-trastuzumab emtansine, trastuzumab
- Target
- HER2 / ERBB2
4 starting configurations Model details
Alemtuzumab
continuous Petri-net reconstructionformal immune network Monoclonal antibody Autoimmune diseaseImmunology & inflammation
Alemtuzumab and T-cell network recovery
Explore treatment-driven peripheral immune recovery and CNS accumulation under explicitly defined continuous network configurations.
- Therapeutic
- Alemtuzumab
- Target
- CD52
14 starting configurations Model details
anakinra
apparent one-compartment SC PKconditional indirect CRP response Other biologic or therapeutic modality Immunology & inflammation
Anakinra exposure and conditional CRP turnover
Reference paper ↗Apparent subcutaneous anakinra exposure inhibits empirical CRP production. Fixed responder and waning-sensitivity groups distinguish sustained suppression from rebound under a constant or PK-derived concentration driver.
- Therapeutic
- anakinra
- Target
- IL1R1
6 starting configurations Model details
Anti-CD66 antibody BW250/183
Monoclonal antibody OncologyHematology
Anti-CD66 · fixed antigen constraint1
Reference paper ↗Fixed antibody distribution, mono/bivalent CD66 binding, single-radiolabel turnover and finite-window measurement accounting.
- Therapeutic
- Anti-CD66 antibody BW250/183
- Target
- CD66
9 starting configurations Model details
Monoclonal antibody OncologyHematology
Anti-CD66 · fixed antigen constraint2
Reference paper ↗Fixed antibody distribution, mono/bivalent CD66 binding, single-radiolabel turnover and finite-window measurement accounting.
- Therapeutic
- Anti-CD66 antibody BW250/183
- Target
- CD66
9 starting configurations Model details
Anti-TargetX antibody
conditional reduced QSPantibody–soluble-target binding Monoclonal antibody Neurology & neurodegeneration
Rat-brain antibody and target response — reduced companion
Explore local antibody expression, reversible target binding and turnover in three independent concentration systems.
- Therapeutic
- Anti-TargetX antibody
- Target
- TargetX (anonymized target)
11 starting configurations Model details
ATC161
PK/PD Targeted protein degrader Neurology & neurodegeneration
ATC161 exposure and alpha-synuclein aggregate degradation
Reference paper ↗A reduced AUTOTAC PK/PD model linking ATC161 exposure to concentration-dependent degradation and recovery of alpha-synuclein aggregates.
- Therapeutic
- ATC161
- Target
- alpha-synuclein aggregates, SNCA aggregates, p62, SQSTM1
1 starting configuration Model details
Atezolizumab
PK Monoclonal antibody OncologyImmuno-oncology
Atezolizumab exposure across pediatric and young-adult cohorts
Reference paper ↗Two-compartment IV atezolizumab exposure with fixed weight, albumin, tumor-burden and ADA effects. Explicit finite infusions and cohort-specific source domains support conditional exploration.
- Therapeutic
- Atezolizumab
- Target
- PD-L1 / CD274
16 starting configurations Model details
Conditional circulating PKFixed covariatesConstant clearance Monoclonal antibody OncologyImmuno-oncology
Atezolizumab PK: baseline patient profiles
Reference paper ↗Compare circulating atezolizumab exposure under fixed patient covariates and constant clearance. The released two-compartment model includes intravenous infusions and cumulative exposure.
- Therapeutic
- Atezolizumab
- Target
- PD-L1 / CD274
4 starting configurations Model details
Conditional serum PKFixed covariatesTime-varying clearance Monoclonal antibody OncologyImmuno-oncology
Atezolizumab PK: standard and loading schedules
Reference paper ↗Compare serum atezolizumab exposure across the released dosing schedules, with fixed patient covariates and time-varying clearance.
- Therapeutic
- Atezolizumab
- Target
- PD-L1 / CD274
6 starting configurations Model details
AZD7442 (total-antibody analyte)
Two-compartment PKFixed covariates Monoclonal antibody Respiratory diseaseInfectious disease
AZD7442 total-antibody pharmacokinetics
Reference paper ↗Two-compartment total-serum PK with explicit IM/IV administration, fixed covariates and empirical input-weighted amount accounting.
- Therapeutic
- AZD7442 (total-antibody analyte)
- Target
- SARS-CoV-2 Spike RBD
20 starting configurations Model details
Befovacimab
PK/PDTMDD Monoclonal antibody HematologyCardiovascular & coagulation
Befovacimab PK and TFPI target binding
Reference paper ↗A QSS-TMDD model representing intravenous or subcutaneous befovacimab disposition, TFPI turnover, free antibody, and antibody–TFPI complex dynamics.
- Therapeutic
- Befovacimab, BAY 1093884 / befovacimab
- Target
- TFPI, tissue factor pathway inhibitor
5 starting configurations Model details
Bevacizumab
QSS bindingTarget turnoverFixed allometry Monoclonal antibody OncologyCardiovascular & coagulation
Bevacizumab and VEGF165 conditional QSS binding
Reference paper ↗Specified QSS binding, free-drug distribution and VEGF turnover with separate drug and target accounting.
- Therapeutic
- Bevacizumab
- Target
- VEGF-A, VEGF165
12 starting configurations Model details
Two-compartment PKFixed allometry Monoclonal antibody Oncology
Bevacizumab conditional pharmacokinetics
Independent two-compartment total-bevacizumab PK with fixed allometry and drug accounting.
- Therapeutic
- Bevacizumab
- Target
- VEGF-A, VEGF165
8 starting configurations Model details
Constructed conditional PKFixed profilesLinear two-compartment Monoclonal antibody General pharmacology
Bevacizumab exposure: adult and pediatric reference profiles
Reference paper ↗Compare constructed two-compartment bevacizumab exposure profiles across the released adult and pediatric reference cases. These fixed profiles do not simulate a mechanistic pediatric PBPK bridge.
- Therapeutic
- Bevacizumab
- Target
- VEGF-A
10 starting configurations Model details
Blinatumomab and comparator T-cell agonists
QSP Bispecific antibody / T-cell engager Immunology & inflammation
T-cell-engager cytokine-release network
Reference paper ↗A cytokine-network QSP model coupling drug exposure to resting, activated, cytotoxic, and exhausted T cells and to IL-6, IL-10, IL-1beta, IFN-gamma, and TNF-alpha dynamics.
- Therapeutic
- Blinatumomab and comparator T-cell agonists
- Target
- CD19, CD3, CD28, IL-6R / CD126
4 starting configurations Model details
Cemiplimab
Two-compartment PKTime-varying clearanceFixed covariates Monoclonal antibody OncologyImmuno-oncology
Cemiplimab pharmacokinetics with time-varying clearance
Reference paper ↗Two-compartment IV disposition with fixed baseline covariates, specified individual effects and integrated drug elimination.
- Therapeutic
- Cemiplimab
- Target
- PD-1 / PDCD1
34 starting configurations Model details
Certolizumab pegol
Antibody fragment Autoimmune diseaseImmunology & inflammation
Certolizumab pegol subcutaneous PK
Reference paper ↗A reduced subcutaneous PK model representing certolizumab pegol absorption from a depot, systemic elimination, blood concentration, and cumulative exposure.
- Therapeutic
- Certolizumab pegol
- Target
- TNF / TNFA, P01375
2 starting configurations Model details
Cilgavimab
Conditional component PKFixed covariates Monoclonal antibody Respiratory diseaseInfectious disease
Cilgavimab serum pharmacokinetics
Explore serum cilgavimab exposure with fixed patient covariates using the publication’s main coefficient profile. Alternative coefficient estimates and population variability are outside this reference model.
- Therapeutic
- Cilgavimab
- Target
- SARS-CoV-2 Spike RBD
4 starting configurations Model details
Crenezumab
Reduced conditional PKCentral target turnoverMichaelis–Menten approximation Monoclonal antibody Neurology & neurodegeneration
Crenezumab PK and plasma Aβ turnover
Reference paper ↗Explore crenezumab exposure and plasma amyloid-beta turnover after the specified intravenous administrations. This reduced two-compartment model tracks drug and target amounts separately.
- Therapeutic
- Crenezumab
- Target
- Amyloid beta / APP, beta-amyloid, Abeta(1-40), Abeta(1-42)
3 starting configurations Model details
dabigatran and idarucizumab
Antibody fragment General pharmacology
Dabigatran exposure and empirical idarucizumab reversal in sheep
Reference paper ↗Two dabigatran amount pools, delayed coagulation response and a separately administered empirical reversal effect in fixed sheep research contexts.
- Therapeutic
- dabigatran and idarucizumab, idarucizumab
- Target
- dabigatran-associated coagulation response
30 starting configurations Model details
